New Zealand’s Supreme Health has cultivated a unique strain of Haematococcus pluvialis in Nelson Lakes, northern New Zealand, for the production of natural astaxanthin.

Israeli-based Algatechnologies, Ltd. (Algatech) has become the major shareholder in Supreme Health New Zealand, Ltd. (Supreme) to supply the rapidly growing markets in China and Asia-Pacific with astaxanthin and other algae-based products.

Algatech, located in the Arava desert in Israel, is a rapidly growing company specializing in the commercial cultivation of microalgae. It is a leading manufacturer of natural astaxanthin, marketed in 35 countries under its AstaPure® brand. The company will be providing its know-how, innovative science, and advanced microalgae cultivation technologies to leverage the capabilities of the New Zealand-based company.

Led by CEO Kerry Paul, the former founder and CEO of Manuka Health New Zealand, Supreme has strong recognition for its cutting-edge science and its natural astaxanthin — a unique strain of Haematococcus pluvialis found in Nelson Lakes, northern New Zealand.

With marketing channels in China, New Zealand, and Australia, Supreme will focus on marketing microalgae ingredients and astaxanthin-based products to food, dietary supplement, and cosmetic industries throughout Asia-Pacific, with special emphasis on China.

“This investment is in line with our core strategy to expand the potential of microalgae derived products, especially natural astaxanthin, which is our key ingredient,” said Hagai Stadler, CEO of Algatech. “Collaborating with Supreme allows us to increase our service of Asia-Pacific, especially in China. We identified a rapidly growing interest in those regions for quality astaxanthin and other quality algae-delivered products.”

“We believe that the synergy between companies, together with Mr. Paul’s wide experience and proven track record, will help Supreme to become a major player in the global market,” said Algatech chairman Ed Hofland, who will also serve as Supreme’s president.